Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Shore, Neal D.
Craver, Christopher
Blanc, Simon
Sathyan, Pratheesh
Aton, Lindsay
Varughese, Prateesh
Tierno, Marni Brisson
机构：
[1] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[2] Integra Connect, W Palm Beach, FL USA
[3] Integra Connect PrecisionQ, W Palm Beach, FL USA
[4] Illumina Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-2494-5577-2829-12292; 613-225-3248-9542-9243; 130-544; 613-4678-416-5229; 298-11050; 3282-206-4957-326-2356-4994; 9; 7; 6; 3; 2; 109; 1; 38092-20446; 38092-18438; 38092-35367; 38092-20212; 38092-18853;
D O I：
10.1200/JCO.2024.42.4_suppl.210
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [31] Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Lumen, Nicolaas
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    van den Berg, Erik
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [33] Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.
    Higano, Celestia S.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand F.
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] PROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm)
    Sandhu, Shahneen
    Hussain, Maha
    Mateo, Joaquin
    Fizazi, Karim
    Saad, Fred
    Shore, Neal
    Chi, Kim
    Sartor, Oliver
    Agarwal, Neeraj
    Olmos, David
    Thiery-Vuillemin, Antoine
    Twardowski, Przemyslaw
    Mehra, Niven
    Goessl, Carsten
    Kang, Jinyu
    Burgents, Joseph
    Wu, Wenting
    Kohlmann, Alexander
    Adelman, Carrie
    De Bono, Johann
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 122 - 122
  • [35] Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
    Olmos, D.
    Lorente, D.
    Alameda, D.
    Cattrini, C.
    Romero-Laorden, N.
    Lozano, R.
    Lopez-Casas, P. P.
    Jambrina, A.
    Capone, C.
    Vanden Broecke, A. M.
    Trevisan, M.
    Van Sanden, S.
    Juergens, A.
    Herrera-Imbroda, B.
    Castro, E.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 458 - 472
  • [36] Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).
    Barata, Pedro C.
    Montgomery, Rachel
    Last, Matthew
    Gillespie-Akar, Liane
    Nazari, Jonathan
    Arondekar, Bhakti
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer
    Gupta, Shilpa
    To, Tu My
    Graf, Ryon
    Kadel, Edward E.
    Reilly, Norelle
    Albarmawi, Husam
    JCO PRECISION ONCOLOGY, 2024, 8
  • [38] REAL-WORLD DATA ANALYSIS OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATMENT DECISIONS WITH THE INTRODUCTION OF NEWER TREATMENT OPTIONS
    Scott, J.
    Concepcion, R.
    Garofalo, D.
    Verma-Kurvari, S.
    Xu, B.
    Montgomery, J.
    VALUE IN HEALTH, 2018, 21 : S43 - S43
  • [39] Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial
    Shore, Neal D.
    Clarke, Noel
    Armstrong, Andrew J.
    Oya, Mototsugu
    Procopio, Giuseppe
    Guedes, Joao Daniel Cardoso
    Arslan, Cagatay
    Mehra, Niven
    Brown, Emma
    Schluermann, Friederike
    Joung, Jae Young
    Sugimoto, Mikio
    Vianna, Karina
    Hosius, Christian
    Barnicle, Alan
    Liu, Yu-Zhen
    Harrington, Elizabeth
    McGuinness, David
    del Rosario, Paula Michelle
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 165 - 165
  • [40] REAL-WORLD TREATMENT PATTERNS AND TREATMENT SEQUENCES IN THE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER SETTINGS ACROSS EUROPE
    Castro, E.
    Orji, C.
    Ribbands, A.
    Butcher, J.
    Walley, M.
    Li, W.
    Ghate, S.
    VALUE IN HEALTH, 2024, 27 (06) : S227 - S227
12345